Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia
CompletedOBSERVATIONAL
Enrollment
107
Participants
Timeline
Start Date
January 31, 2007
Primary Completion Date
June 30, 2012
Study Completion Date
October 31, 2012
Conditions
Primary Immune Thrombocytopenia
All Listed Sponsors
lead
Henri Mondor University Hospital
OTHER
NCT01727232 - Efficacy and Safety of Rituximab Given at Fixed Dose (1000 mg on Days 1 and 15) Compared to the Standard Regimen in Adult's Immune Thrombocytopenia | Biotech Hunter | Biotech Hunter